A New Approach to Rare Disease Clinical Trials
Originally published on Triple Pundit Research studies that test potential treatments for rare diseases have long faced excessive costs, prolonged timelines and a staggering failure rate. One frequently cited 2019 analysis found that over half of randomized controlled trials studying rare diseases — defined as conditions affecting fewer than six patients per 10,000 people — are ultimately […]
Why 55% of Clinical Trials Fail – The Truth About Drug Development
Have you ever wondered why so many clinical trials fail before reaching the market? In this episode, we dive deep into the hidden challenges of clinical trials with Rob Freishtat, President and Co-Founder of Uncommon Cures and a professor at George Washington University School of Medicine and Health Sciences. Rob shares insider knowledge on why […]
Rob Freishtat- Revolutionizing Clinical Trials in Rare Disease: Efficiency and Patient-Centric Solutions
In this episode, Leanne Woelke chats with Rob Freishtat, Co-Founder and President of Uncommon Cures and former emergency physician. Rob shares his journey into the world of rare disease clinical research and his mission to transform the clinical trial landscape. They discuss the unique challenges of diagnosing and treating rare diseases and the critical role […]
Uncommon Cures and Carexso Partner to Expand Orphan Drug Clinical Trials in the Middle East
Originally published on EIN Presswire CHEVY CHASE, MD, UNITED STATES, December 17, 2024 /EINPresswire.com/ — Chevy Chase, MD, 17 December 2024 – Uncommon Cures, an organization at the forefront of accelerating the development of orphan drugs, has entered into a strategic collaboration with Carexso, a leading Site Management organization based in the United Arab Emirates […]
Uncommon Cures and TASK Partner to Advance Clinical Trials for Orphan Drugs Across Europe and South Africa
Chevy Chase, MD, 2 December 2024 – Uncommon Cures®, a pioneering organization dedicated to accelerating the development of orphan drugs, has announced a strategic collaboration with TASK, a leading global clinical research organization specializing in various therapeutic areas. This collaboration will combine Uncommon Cures’ innovative approaches to orphan drug development with TASK’s extensive clinical trial […]
Uncommon Cures, LLC Begins Operations With Series A Funding To Bring Cost-Effective And Time-Efficient Clinical Trials To The Rare Disease Field.
Uncommon Cures, LLC, a privately held rare disease clinical research organization (CRO), begins operations after completing its Series A financing led by PilotRock Investments, LLC. Uncommon Cures brings together a team of rare disease physicians with over 75 years of combined experience and a deeply experienced clinical trials team. Uncommon Cures’ mission is to reduce […]